{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:34:51Z","timestamp":1788863691207,"version":"build-2803163510"},"reference-count":13,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jtha.2023.07.019","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T06:14:06Z","timestamp":1691043246000},"page":"2771-2775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII"],"prefix":"10.1016","volume":"21","author":[{"given":"Andreas","family":"Hillarp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l A.","family":"Holme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik P.","family":"W\u00e5land","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie S.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola E.","family":"Henriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir E.","family":"Tj\u00f8nnfjord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragnhild J.","family":"M\u00e5seide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.07.019_bib1","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.07.019_bib2","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1111\/hae.14297","article-title":"Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study","volume":"27","author":"Reding","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.07.019_bib3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/hae.14294","article-title":"PROTECT VIII kids extension study: long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A","volume":"27","author":"Mancuso","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.07.019_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12674","article-title":"Turoctocog alfa pegol (N8-GP) in severe hemophilia A: long-term safety and efficacy in previously treated patients of all ages in the pathfinder8 study","volume":"6","author":"Lentz","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.07.019_bib5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0038-1653759","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability","volume":"73","author":"Verbruggen","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.07.019_bib6","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1055\/s-0037-1615080","volume":"79","author":"Giles","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.07.019_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2516.2012.02903.x","article-title":"Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A","volume":"19","author":"Klintman","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.07.019_bib8","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal Chem"},{"key":"10.1016\/j.jtha.2023.07.019_bib9","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/bloodadvances.2022007529","article-title":"The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A","volume":"7","author":"Male","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.07.019_bib10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/bloodadvances.2022008989","article-title":"Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination","volume":"7","author":"Valsecchi","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.07.019_bib11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/hae.14786","article-title":"Intra-articular haemorrhage caused by reduced recovery of pegylated recombinant factor VIII due to an anti-PEG antibody developed after mRNA-1273 SARS-CoV-2 vaccination in haemophilia A","volume":"29","author":"Nakajima","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.07.019_bib12","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1111\/hae.13963","article-title":"PROTECT VIII kids: BAY 94-9027 (PEGylated recombinant factor VIII) safety and efficacy in previously treated children with severe haemophilia A","volume":"26","author":"Santagostino","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.07.019_bib13","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s11095-016-1961-x","article-title":"The mystery of antibodies against polyethylene glycol (PEG) - what do we know?","volume":"33","author":"Lubich","year":"2016","journal-title":"Pharm Res"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623005822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623005822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T03:00:34Z","timestamp":1742266834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623005822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1538783623005822"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.07.019","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}